Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

作者: C. Mura , N. Gerard , M. Vincent-Viry , MM Galteau , E. Jacqz-Aigrain

DOI: 10.1111/J.1365-2125.1993.TB05681.X

关键词: Allele frequencyGeneticsMinor allele frequencyRestriction fragment length polymorphismLocus (genetics)AlleleGenotypeFixed alleleMolecular biologyCYP2D6Biology

摘要: 1. Cytochrome P450 debrisoquine (CYP2D6) activity is polymorphic and under genetic control. Most Caucasians are extensive metabolizers, but 5%-10% poor metabolizers. 2. Restriction fragment length polymorphism analysis of the CYP2D6 locus identifies a 29kb XbaI fragment, either normal (D6-wt) or mutated, three mutated alleles (44kb, 11.5kb 16 + 9kb). The 44kb allele was initially considered as metabolizer owing to D6-B mutation, cases not carrying D6-B, therefore potentially functional, have been found. degree molecular heterogeneity this investigated by phenotype genotype families. 3. Thirty-one French Caucasian families, representing 117 individuals, possessing at least one in each family were selected. Phenotypes determined using dextromethorphan, XbaI, NcoI BamH1 RFLPs 42 independent chromosomes analyzed. 4. 80% carried CYP2D6-B mutation had an additional (12.5kb 4.8kb). remaining 20% did carry A mutations no extra fragment. 5. Information on families demonstrated that associated with phenotype. 6. We conclude substantial percentage functional CYP2D gene, therefore, consistently metaboliser allele.

参考文章(24)
U A Meyer, M Blum, R Gaedigk, A Gaedigk, M Eichelbaum, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. American Journal of Human Genetics. ,vol. 48, pp. 943- 950 ,(1991)
U A Meyer, S Kimura, R C Skoda, F J Gonzalez, M Umeno, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. American Journal of Human Genetics. ,vol. 45, pp. 889- 904 ,(1989)
Frank J Gonzalez, Urs A Meyer, Molecular genetics of the debrisoquin-sparteine polymorphism Clinical Pharmacology & Therapeutics. ,vol. 50, pp. 233- 238 ,(1991) , 10.1038/CLPT.1991.131
M. Eichelbaum, A.S. Gross, The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects Pharmacology & Therapeutics. ,vol. 46, pp. 377- 394 ,(1990) , 10.1016/0163-7258(90)90025-W
K. Br�sen, L. F. Gram, Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology. ,vol. 36, pp. 537- 547 ,(1989) , 10.1007/BF00637732
R. C. Skoda, F. J. Gonzalez, A. Demierre, U. A. Meyer, Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 85, pp. 5240- 5243 ,(1988) , 10.1073/PNAS.85.14.5240
C. Mura, JP Broyard, E. Jacqz-Aigrain, R. Krishnamoorthy, Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese. British Journal of Clinical Pharmacology. ,vol. 32, pp. 135- 136 ,(1991) , 10.1111/J.1365-2125.1991.TB05629.X
Urs A. Meyer, Radek C. Skoda, Ulrich M. Zanger, The genetic polymorphism of debrisoquine/sparteine metabolism—molecular mechanisms Pharmacology & Therapeutics. ,vol. 46, pp. 297- 308 ,(1990) , 10.1016/0163-7258(90)90096-K